SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

AMBROSIO, Maria Rosaria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.646
AS - Asia 7.896
EU - Europa 6.254
SA - Sud America 1.402
AF - Africa 126
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 8
Totale 30.343
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.307
SG - Singapore 3.385
CN - Cina 2.329
DE - Germania 2.276
BR - Brasile 1.204
IT - Italia 913
UA - Ucraina 840
HK - Hong Kong 779
RU - Federazione Russa 526
GB - Regno Unito 472
TR - Turchia 456
VN - Vietnam 415
FI - Finlandia 395
SE - Svezia 233
PL - Polonia 204
MX - Messico 166
CA - Canada 145
ID - Indonesia 117
FR - Francia 100
IN - India 99
AR - Argentina 84
NL - Olanda 78
JP - Giappone 64
ZA - Sudafrica 63
BD - Bangladesh 57
ES - Italia 50
LT - Lituania 35
BE - Belgio 34
IQ - Iraq 34
AT - Austria 32
EC - Ecuador 28
PK - Pakistan 22
UZ - Uzbekistan 22
VE - Venezuela 22
CO - Colombia 19
MA - Marocco 16
AE - Emirati Arabi Uniti 12
PY - Paraguay 12
EG - Egitto 11
IE - Irlanda 10
MY - Malesia 10
RO - Romania 10
AU - Australia 9
CL - Cile 9
KE - Kenya 9
UY - Uruguay 9
AL - Albania 8
CZ - Repubblica Ceca 8
JO - Giordania 8
NP - Nepal 8
SA - Arabia Saudita 8
TN - Tunisia 8
BO - Bolivia 7
CH - Svizzera 7
DZ - Algeria 6
EU - Europa 6
PE - Perù 6
AZ - Azerbaigian 5
IL - Israele 5
IR - Iran 5
KR - Corea 5
PH - Filippine 5
TH - Thailandia 5
JM - Giamaica 4
KG - Kirghizistan 4
LB - Libano 4
NG - Nigeria 4
OM - Oman 4
PA - Panama 4
PS - Palestinian Territory 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
AM - Armenia 3
CR - Costa Rica 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
GR - Grecia 3
LK - Sri Lanka 3
LV - Lettonia 3
TW - Taiwan 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BY - Bielorussia 2
CY - Cipro 2
ET - Etiopia 2
GT - Guatemala 2
HN - Honduras 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
QA - Qatar 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BH - Bahrain 1
EE - Estonia 1
GA - Gabon 1
Totale 30.328
Salva come PNG Salva come JPEG
Città #
Singapore 1.926
Ashburn 1.521
Woodbridge 1.317
Fairfield 1.155
Chandler 1.111
Jacksonville 897
Santa Clara 812
Beijing 799
Houston 798
Hong Kong 776
Ann Arbor 506
Wilmington 443
Seattle 442
Cambridge 359
Munich 317
Los Angeles 288
Izmir 279
New York 278
Dallas 275
Nanjing 265
Princeton 227
Addison 216
Warsaw 198
San Diego 154
Milan 152
Shanghai 146
Ferrara 142
Ho Chi Minh City 133
São Paulo 131
Helsinki 125
Mexico City 118
Boardman 116
Hanoi 103
Turku 91
Jakarta 87
Shenyang 78
Hebei 70
London 70
Nanchang 70
Hefei 69
Washington 67
Bremen 66
Chicago 61
Tokyo 59
Dearborn 56
Buffalo 55
Tianjin 55
Brooklyn 54
Denver 53
Changsha 52
Moscow 50
Montreal 46
Mountain View 46
Chennai 45
Stockholm 44
Jiaxing 43
Johannesburg 41
San Francisco 41
Toronto 41
Boston 39
Orem 39
Falls Church 37
Phoenix 37
Bologna 36
Rome 36
Atlanta 35
Redwood City 35
Brussels 34
Poplar 34
Rio de Janeiro 34
Jinan 33
Kunming 33
Frankfurt am Main 31
Belo Horizonte 27
Guangzhou 27
Manchester 26
Nuremberg 25
Ankara 24
Ningbo 24
Norwalk 23
The Dalles 23
Zhengzhou 22
Falkenstein 21
Brasília 20
Campinas 19
Des Moines 18
Ottawa 18
San Mateo 18
Modena 17
Amsterdam 16
Curitiba 16
Haiphong 16
Tashkent 16
Hangzhou 15
Orange 15
Tappahannock 15
Auburn Hills 14
Council Bluffs 14
Guarulhos 14
Querétaro 14
Totale 19.045
Salva come PNG Salva come JPEG
Nome #
Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds 282
Applicability of laparoscopic approach to the resection of large adrenal tumours: a retrospective cohort study on 200 patients 251
Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas 237
A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization 219
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids 209
Recettori della somatostatina e carcinoma midollare della tiroide: prospettive future. 205
Circadian profile of plasma calcitonin gene-related peptide in healthy man 200
Effect of deltorphin on pituitary-adrenal response to insulin-induced hypoglycemia and ovine corticotropin-releasing hormone in healthy man 200
Predictors of Pituitary Dysfunction in Patients Surviving Ischemic Stroke 200
Circadian rhythm of calcitonin gene-related peptide in uncomplicated essential hypertension 193
Acute lowering of plasma GH concentrations by somatostatin is associated with activation of pituitary-adrenal-axisin healthy young and elderly subjects 193
Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region 191
Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells 190
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion 189
mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 185
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression 182
Activation of the somatotropic axis by testosterone in adult men: evidence for a role of hypothalamic growth hormone (GH)- releasing hormone function 174
Efficacy and safety of the new 60 mg formulation of the long acting somatostatin analog lanreotide in the treatment of acromegaly. 173
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. 172
Acute administration of human galanin in normal subjects reduces the potentiating effect of pyridostigmine-induced cholinergic enhancement on release of norepinephrine and pancreatic polypeptide 171
Growth hormone excess promotes breast cancer chemoresistance 171
X-linked acrogigantism syndrome: clinical profile and therapeutic responses 171
DELTA-OPIOID RECEPTOR MODULATION OF THE HYPOTHALAMIC -PITUITARY-ADRENOCORTICAL AXIS 170
Growth hormone induces chemoresistance in breast cancer cells 169
Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion 169
R171Q MEN1 polymorphism in patients presenting with hyperparathyroidism 169
Antiproliferative effects of somatostatin analogs in pituitary adenomas 168
Evaluation of hormonal function in a series of incidentally discovered adrenal masses 166
Diurnal rhythm of plasma catecholamines in acromegaly 166
Therapeutic concentrations of mitotane (o,p′-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model 164
RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease 164
Unexpected activation of pituitary-adrenal axis in healthy young and elderly subjects during somatostatin infusion 162
Effects of octreotide on gallbladder motor function in acromegaly 162
Deletion of exons 1-3 of the MEN1 gene in a large Italian family causes the loss of menin expression 161
Evidence that enhancement of cholinergic tone increases basal plasma levels of calcitonin gene-related peptide in normal man 159
A defective hypothalamic GHRH activity may contribute to declining GH secretion wuth age in man 159
Growth Hormone Enhances Breast Cancer Chemoresistance by Inhibiting JNK-Mediated Apoptosis 159
Pituitary side effects of old and new drugs. 159
Neck paraganglioma and follicular lymphoma: A case report 159
Recettori della Somatostatina e Carcinoma Midollare della Tiroide: prospettive future. 158
A new VHL polymorphism in a big family from Ferrara 157
In vitro testing of new somatostatin analogs on pituitary tumor cells 153
Evaluation of bone markers and structure in subclinical Cushing’s syndrome 153
ADRENAL INCIDENTALOMA: CLINICAL AND METABOLIC ASPECTS DURING LONG-TERM FOLLOW-UP 153
Cerebral aneurysm and acromegaly: a case report 152
Atypical femoral fractures as a complication of long-term bisphosphonate therapy 152
Efficacy of tolvaptan treatment in a patient with syndrome of inappropriate antidiuresis (SIAD) after severe traumatic brain injury 152
Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS) 152
Growth hormone and skeletal muscle function 151
Prevalence and predictive factors of anterior hypopituitarism after ischemic stroke. 151
Cardiac and metabolic effects of chronic GH and IGF1 excess in young adults with pituitary gigantism 151
EFFECTS OF SOMATOSTATIN ANALOG TREATMENT ON GLUCOSE METABOLISM IN ACROMEGALY 150
Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI) 150
Effect of delta-opioid receptor agonist deltorphin on circulating concentrations of luteinizing hormone and follicle stimulating hormone in healthy fertile women 149
Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience 148
GH enhances breast cancer chemoresistance by inhibiting JNK-mediated apoptosis 148
Chromogranin A as a marker of neuroendocrine neoplasia: An Italian Multicenter Study 148
A tool to predict survival in stage IV entero-pancreatic NEN 146
RISK FACTORS FOR DEVELOPING HYPOPITUITARISM AFTER STROKE 145
Blood GH-binding protein levels in premenopausal and postmenopausal women: role of body weight and estrogen levels 144
Efficay and safety of everolimus in metastatic gastroenteropancreatic neuroendocrine tumors 144
Post-stroke inflammatory response may influence pituitary function in patients with brain ischemic and hemorrhagic injury 144
Efficacy, safety and adherence to treatment of teriparatide: an observational study 144
Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame 144
Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF-κB 143
Functional hypothalamic and drug-induced amenorrhea: an overview 143
Endogenous estrogen status significantly influences the nutrition-related alterations in Growth Hormone-Binding protein levles in healthy women 142
Le alterazioni pressorie nell'acromegalia: fattori umorali 142
Role of Piuitary Tumour Transforming Gene 1 in medullary thyroid carcinoma 141
Glucose metabolism alterations in acromegaly 141
Dual-energy X-ray absorptiometry pitfalls in Thalassemia Major 141
Delta opioid receptor involvement in endocrine pathophysiology 140
Growth Hormone enhances breast cancer chemoresistance by protecting from apoptosis 140
GH influences breast cancer chemoresistanec independently of cell cycle perturbations 140
Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients 139
Cerebrovascular disease and GH-IGF-i axis function 137
Inflammatory cytokines and neurotrophic factors correlate with pituitary function after stroke 136
Prevalence of hyopituitarism in post-acute and chronic phase of hemorrhagic stroke 135
Real-world study of everolimus in advanced progressive neuroendocrine tumors 135
Lumbar spine mineral density Z-score discrepancy by DXA and QCT in thalassaemic major patients 135
ASSE GH-IGF-I NELL'INVECCHIAMENTO 134
Everolimus reduces human ACTH-secreting pituitary adenoma in vitro cell viability 134
ASYMPTOMATIC HYPERCALCITONINEMIA IN A PANCREATIC ENDOCRINE CARCINOMA ASSOCIATED WITH A PAPILLARY THYROID CANCER 133
Everolimus reduces human ACTH secreting pituitary adenoma in vitro cell viability by inhibiting IGF-I down-stream signalling 132
Dopamine receptor 2 activation reduces cells viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion 132
Percutaneous Laser Ablation of Liver Metastases from Neuroendocrine Neoplasm. A Retrospective Study for Safety and Effectiveness 132
Interrelationships between calcitonin gene-related peptide and sympathoadrenomedullary system: Effects of administration of epinephrine and norepinephrine in healthy man 131
Replacement therapy and quality of life improvement in adult GHD patients 131
Modulatory effect of the renin-angiotensin system on the plasma levels of calcitonin gene-related peptide in normal man 130
Multiple somatostatin receptor subtypes activation reduces cell viability in non-functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion 130
null 130
Ovarian tumors secreting insulin 128
Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function. 128
Bone metastases frequency, distribution, clinical and imaging characteristics in neuroendocrine tumors: our experience 127
Prevalence of hypopituitarismin patients with cerebrovascular diseases 126
Apoplessie in una casistica di adenomi ipofisari 126
GH protects breast cancer cells from chemotherapy by blocking cytotoxic-induced apoptosis in estrogen receptor negative breast cancer cells 125
Somatostatin receptor subtype 1 selective activation in human growth hormone- and prolactin-secreting pituitary adenomas: effects on cell viability, growth hormone and prolactin secretion. 124
PKCδ plays an important in regulating human medullary thyroid carcinoma cell viability 122
RELIABILITY OF QUANTITATIVE ULTRASOUND IN THE FOLLOW-UP OF ADULTS WITH GH DEFICIENCY UNDERGOING REPLACEMENT THERAPY 121
Totale 15.688
Salva come PNG Salva come JPEG
Categoria #
all - tutte 148.146
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 11.026
Totale 159.172
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.242 0 0 0 0 0 212 64 235 66 269 288 108
2021/20221.981 58 208 114 57 89 90 96 90 79 162 187 751
2022/20232.357 234 221 90 310 328 341 127 205 282 26 119 74
2023/20241.350 108 142 73 41 102 263 48 150 45 30 31 317
2024/20255.557 157 149 427 183 640 580 206 198 906 687 782 642
2025/20268.090 1.472 611 1.302 1.891 2.491 323 0 0 0 0 0 0
Totale 30.680